Substituted 3-benzoylacrylamido-cephalosporanic acid derivative

Abstract

The invention provides anti-bacterial agents of the formula: ##SPC1##R.sup.1 is a member selected from the group consisting of --Cl and ##SPC2##R.sup.2 is a member selected from the group consisting of --H and acetoxy; andM is a member selected from the group consisting of --H, an alkali metal and --NH.sub.4.

Description

BACKGROUND OF THE INVENTION

Certain .alpha., .beta.-unsaturated amides of 7-aminocephalosporanic acid are disclosed in Japanese Patent No. 16,950/66 (Sept. 26, 1966) as abstracted in Derwent 23,236.

DESCRIPTION OF THE INVENTION

In accordance with this invention there is provided a group of anti-bacterial agents of the formula: ##SPC3##

In which R.sup.1 is a member selected from the group consisting of --Cl and ##SPC4## R.sup.2 is a member selected from the group consisting of --H and acetoxy; and M is a member selected from the group consisting of --H, and alkali metal and --NH.sub.4.

The compounds of this invention are prepared by known techniques, in that the 3-(p-substituted benzoyl) acrylic acid is coupled with the 7-amino-cephalosporanic acid derivatives by the mixed anhydride method commonly employed in the formation of amide linkages in polypeptide chemistry.

The compounds of this invention were proven to be effective anti-bacterial agents against gram-positive, gram-negative and resistant strains of bacteria, by testing them in the well known and scientifically accepted agar serial dilution testing technique. Thus, the compounds of this invention are useful in the fields of comparative pharmacology and in microbiology and for the treatment of bacterial infections amenable to treatment with cephalosporin antibiotics.

The following examples illustrate the preparation of representative cephalosporin derivatives within the ambit of the generic aspect of the invention. The activity of each product is presented for those specific bacterial strains against which the compound exemplified was active in providing 100 percent growth inhibition at or below 250 micrograms per milliliter. The representative nature of the bacterial strains employed to demonstrate antibacterial activity are indicative of the broader applicability of the compounds of this invention in the control of bacterial infestations other than those specifically referred to in each of the following examples. The bacteria are named, followed by the specific strain and the concentration in micrograms per milliliter at which 100 percent inhibition occurred. The abbreviations for each bacterium are:

BA SU Bacillus subtilisHE SP Herellea speciesNE CA Neisseria catarrhalisST AU Staphylococcus aureus

EXAMPLE I

7-[3-(p-Chlorobenzoyl)acrylamido]cephalosporanic acid

To a tetrahydrofuran solution of 1.08 grams (5 millimole) of 3-(p-chlorobenzoyl) acrylic acid in a salt-ice bath was added triethylamine (0.50 gram), followed by 0.70 gram (5 millimole) of isobutyl chloroformate. After the solution was stirred for 15 minutes a cold solution of 1.36 grams (5 millimole) 7-amino-cephalosporanic acid and 0.50 gram of triethylamine in 20 milliliters tetrahydrofuran and 10 milliliters H.sub.2 O was slowly added. The mixture was stirred in the ice bath for 1 hour and at room temperature for 1 hour. After filtration of a solid the filtrate was evaporated under reduced pressure at approximatly 30.degree.C. The residue was partly dissolved in 50 milliliters H.sub.2 O and filtered. The aqueous filtrate was acidified with a 6N HCl solution. The resultant precipitate was collected and washed well with H.sub.2 O. The solid was dissolved in ethyl acetate, and the solution dried over anhydrous MgSO.sub.4. After the solvent was removed the residual solid was treated with pentane and collected to give 1.5 grams of the title compound.

Elemental Analysis for C.sub.20 H.sub.17 C1N.sub.2 O.sub.7 S: Calc'd: C, 51.68; H, 3.69; N, 6.03. Found: C, 52.15; H, 4.01; N, 5.65.

______________________________________BA SU 6633 1.95HE SP 9955 250ST AU 6538P 1.95ST AU SMITH 1.95ST AU CHP 7.81ST AU 53-180 15.6______________________________________

EXAMPLE II

7-[3-(p-Chlorobenzoyl)acrylamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

The title compound was prepared by the procedure described in Example 1 except that 7-amino desacetoxycephalosporanic acid was substituted for 7-aminocephalosporanic acid.

Elemental Analysis for C.sub.18 H.sub.17 ClN.sub.2 O.sub.5 S: Calc'd: C, 53.13; H, 3.82; N, 6.89. Found: C, 53.07; H, 3.99; N, 6.68.

______________________________________BA SU 6633 31.3HE SP 9955 250ST AU 6538P 7.81ST AU SMITH 7.81ST AU CHP 31.3ST AU 53-180 31.3______________________________________

EXAMPLE III

7-[3-(4-Biphenylylcarbonyl)acrylamido]cephalosporanic acid

The title compound was prepared by the procedure described in Example 1, except that 3-(4-biphenylylcarbonyl)acrylic acid was substituted for 3-(p-chlorobenzoyl) acrylic acid.

Elemental Analysis for C.sub.26 H.sub.22 N.sub.2 O.sub.7 S: Calc'd: C, 61.68; H, 4.38; N, 5.53. Found: C, 61.97; H, 4.58; N, 5.30.

______________________________________HE SP 9955 250ST AU 6538P .976ST AU SMITH .976ST AU CHP 1.95ST AU 53-180 1.95BA SU 6633 3.90______________________________________

Claims

1. The compound which is 7-[3-(p-chlorobenzoyl)acrylamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.

2. The compound which is 7-[3-(4-biphenylyl-carbonyl)acrylamido]cephalosporanic acid.